subscribeSubscribe
Inhibikase Announces Selection of the Bioequivalent Dose of IkT-001

Inhibikase Announces Selection of the Bioequivalent Dose of IkT-001
PR NEWSWIRE
22 Jun 2023
Share Share
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901

Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901
GLOBENEWSWIRE
11 May 2023
Share Share
Aerami to Investor Day with Leading Experts in Pulmonary Hypertension

Aerami to Investor Day with Leading Experts in Pulmonary Hypertension
GLOBENEWSWIRE
03 Apr 2023
Share Share
Aerami Therapeutics Announces Expansion of the AER-901 Development Program

Aerami Therapeutics Announces Expansion of the AER-901 Development Program
GLOBENEWSWIRE
23 Feb 2023
Share Share
Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL

Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL
Kevin Dunleavy FIERCE PHARMA
15 Feb 2023
Share Share
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901
GLOBENEWSWIRE
21 Dec 2022
Share Share
Qilu Pharmaceutical`s Generic Imatinib Mesylate Receives Approval in US

Qilu Pharmaceutical`s Generic Imatinib Mesylate Receives Approval in US
FDA
21 Jun 2022
Share Share
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix

ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix
Angus Liu FIERCEPHARMA
26 May 2022
Share Share
Qilu`s Generic Imatinib Mesylate Receives Approval in the U.S.

Qilu`s Generic Imatinib Mesylate Receives Approval in the U.S.
FDA
11 Feb 2022
Share Share
Deciphera Presents Results from INTRIGUE Phase 3 Study at ASCO

Deciphera Presents Results from INTRIGUE Phase 3 Study at ASCO
BUSINESSWIRE
24 Jan 2022
Share Share